PCOS Is Now PMOS: What It Means for Your Gut

PCOS Is Now PMOS: What It Means for Your Gut

On May 12, 2026, The Lancet published a landmark paper that officially renamed one of the most common hormonal disorders affecting women, with Polycystic Ovary Syndrome (PCOS) now becoming Polyendocrine Metabolic Ovarian Syndrome (PMOS). Whilst this appears to be merely a one-letter change from "C" to "M," that single letter shift represents a fundamental rethinking of what this condition actually is, and that rethinking places gut health at the centre of understanding and managing it.

For the 170 million women worldwide living with this condition (that's one in eight women), the name change isn't just semantics. It's recognition that the condition was never primarily about ovarian cysts, was never just a reproductive disorder, and has always been a complex metabolic and hormonal disruption affecting multiple body systems.

The new name, and particularly that "M" for metabolic, finally acknowledges what researchers have known for years, which is that this is a whole-body metabolic condition with your gut microbiome sitting at the centre of metabolic health.

Why the Name Changed: Getting It Right After 90 Years

The old name, "Polycystic Ovary Syndrome," created three major problems:

1. It Implied Pathological Cysts (Which Don't Exist)

The "cysts" visible on ultrasound aren't actually cysts -they're arrested follicles, a normal part of the condition's hormonal disruption. The name was medically inaccurate from the start.

2. It Overemphasized the Ovaries

By making ovaries the central feature, the name obscured the condition's broader hormonal, metabolic, and inflammatory nature. Many women with PMOS don't even have polycystic-appearing ovaries on ultrasound, yet the old name suggested this was the defining feature.

3. It Led to Diagnostic Delays and Fragmented Care

Research shows that up to 70% of people with the condition experienced diagnostic delays, often because their symptoms such as weight gain, insulin resistance, inflammation and mood issue didn't fit the narrow "ovarian" framing.

The renaming process involved 14 years of work, input from over 22,000 people (patients and healthcare professionals), and collaboration across 56 international organizations. The result was published in The Lancet in a paper titled "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process."

Breaking Down the New Name: What PMOS Means

Polyendocrine

"Poly" means multiple. "Endocrine" refers to hormones.

PMOS involves disruption of multiple interacting hormonal systems:

  • Insulin (metabolic hormone)
  • Androgens (testosterone and related hormones)
  • Neuroendocrine hormones (affecting mood, stress response, appetite)
  • Reproductive hormones (LH, FSH, estrogen, progesterone)

This isn't one hormone going wrong, it's a complex cascade of hormonal imbalances affecting each other.

Metabolic

This is the crucial addition. And this is where gut health becomes central.

50-70% of people with PMOS have insulin resistance, meaning their cells don't respond properly to insulin. This drives:

  • Weight gain (particularly abdominal)
  • Difficulty losing weight
  • Increased risk of type 2 diabetes
  • Cardiovascular disease risk
  • Chronic inflammation

The "metabolic" component was always there, it just wasn't in the name. Now it is. And metabolism is fundamentally connected to gut microbiome function.

Ovarian

The ovaries are still part of the picture - just not the whole picture.

Hormonal disruption affects ovarian function, leading to irregular periods, difficulty ovulating, and fertility challenges. But the ovaries are responding to the broader hormonal and metabolic dysfunction, not creating it independently.

The Gut-PMOS Connection: Why Metabolism Matters

Here's why that "M" for metabolic is critical and why it points directly to gut health:

Insulin Resistance Is Central to PMOS

Insulin resistance occurs when your cells become less responsive to insulin, requiring your pancreas to produce more and more insulin to achieve the same effect. This creates a state of high circulating insulin (hyperinsulinemia), which:

  • Stimulates ovaries to produce excess androgens (testosterone)
  • Disrupts normal follicle development
  • Interferes with ovulation
  • Drives weight gain
  • Promotes inflammation
  • Increases diabetes and cardiovascular disease risk

And here's the gut connection: Research consistently shows that women with PMOS have distinctly different gut bacteria compared to metabolically healthy women.

The Research: Gut Dysbiosis in PMOS

A pilot study examining gut microbiome structure in PMOS patients with insulin resistance found significant dysbiosis (bacterial imbalance). Specifically, PMOS patients with insulin resistance showed:

  • Reduced diversity of gut bacteria
  • Lower levels of Ruminococcaceae and Lachnospiraceae (beneficial bacteria)
  • Altered steroid hormone biosynthesis pathways
  • Increased lipopolysaccharide biosynthesis (inflammatory compounds)

The study concluded: "Dysbiosis of gut microbial communities occurred most notably in insulin-resistant PMOS patients, and the difference in gut dysbiosis profile should be considered in clinical treatment" (PubMed: 30292647).

Another study examining normal-weight women with PMOS found that those with insulin resistance had distinctly different gut bacteria compared to PMOS patients without insulin resistance and healthy controls. The bacterial changes correlated with degree of insulin resistance (PubMed: 33773586).

How Gut Bacteria Affect Insulin Sensitivity

Your gut microbiome influences insulin sensitivity through several mechanisms:

1. Short-Chain Fatty Acid (SCFA) Production

Beneficial gut bacteria ferment dietary fibre into SCFAs - particularly butyrate, propionate, and acetate. These compounds:

  • Improve insulin sensitivity directly
  • Reduce inflammation
  • Strengthen the intestinal barrier
  • Regulate appetite hormones

Women with PMOS consistently show reduced SCFA-producing bacteria.

2. Intestinal Permeability ("Leaky Gut")

Research proposes a mechanism called DOGMA (Dysbiosis of Gut Microbiota) explaining PMOS development:

  1. High-sugar, high-fat, low-fibre diet disrupts gut bacteria balance
  2. Intestinal barrier weakens (increased permeability)
  3. Bacterial fragments (lipopolysaccharide/LPS) leak into bloodstream
  4. Immune system activates inflammatory pathways
  5. Inflammation interferes with insulin receptor function
  6. Insulin resistance develops

A review examining the gut microbiota-PMOS-insulin resistance connection noted: "Leaky gut may cause leakage of lipopolysaccharide into systemic circulation, and the resultant activation of the immune system might interfere with functioning of insulin receptor, causing insulin resistance" (PMC: PMC7301991).

3. Chronic Inflammation

Dysbiotic gut bacteria produce inflammatory compounds that trigger chronic low-grade inflammation throughout the body. This inflammation directly impairs insulin signalling and contributes to the hormonal disruption seen in PMOS.

A comprehensive review published in 2025 stated: "Recent advances underscore the gut microbiome's critical role in modulating insulin resistance and metabolic homeostasis in PMOS. This review highlights novel insights into gut dysbiosis-driven inflammation, gut-brain hormonal signaling, and immune modulation as underlying mechanisms connecting PMOS with metabolic dysfunction" (PubMed: 40154106).

4. Hormone Metabolism

Gut bacteria directly influence how your body metabolizes and eliminates hormones, including estrogens and androgens. Imbalanced gut bacteria can lead to:

  • Altered estrogen metabolism
  • Increased androgen levels
  • Disrupted hormone clearance

Research examining gut microbiota and serum metabolites in PMOS found: "Characteristic gut microbiota and metabolites may play an important role in the insulin resistance and the mood changes of PMOS patients" (PubMed: 36564416).

What the Name Change Means Practically

For Diagnosis

Focusing on the metabolic component means doctors should assess:

  • Insulin resistance (not just blood sugar)
  • Inflammatory markers
  • Metabolic health markers (lipids, blood pressure)
  • Body composition (not just BMI)

And increasingly, gut health markers should be part of the assessment.

For Treatment

The metabolic framing shifts treatment priorities:

Traditional PCOS treatment focused on:

  • Birth control pills (to regulate periods)
  • Metformin (for insulin resistance)
  • Fertility medications (when trying to conceive)

PMOS metabolic approach includes:

  • Dietary interventions supporting metabolic health
  • Gut microbiome support through fibre and plant diversity
  • Anti-inflammatory nutrition
  • Lifestyle modifications addressing insulin sensitivity
  • Stress management (stress hormones affect both metabolism and gut bacteria)

For Research

Recognizing PMOS as a metabolic condition opens research into:

  • Gut microbiome interventions
  • Prebiotic and fibre supplementation
  • Anti-inflammatory dietary patterns
  • Metabolic markers as treatment targets
  • Preventive strategies before insulin resistance develops

Supporting Metabolic Health Through Gut Health

If PMOS is fundamentally a metabolic disorder, and gut bacteria play a central role in metabolic function, then supporting gut health becomes a logical intervention strategy.

What Research Shows Helps

Dietary Fibre and Plant Diversity

The American Gut Project found that people eating 30+ different plant foods per week had significantly more diverse gut bacteria and more short-chain fatty acid producers—exactly what women with PMOS need (McDonald et al., 2018).

Higher fibre intake is consistently associated with:

  • Improved insulin sensitivity
  • Reduced inflammation
  • Better weight management
  • More diverse gut bacteria

Anti-Inflammatory Foods

Research on dietary emulsifiers (common in ultra-processed foods) shows they damage the intestinal barrier and promote inflammation—worsening the leaky gut mechanism that may drive PMOS (Chassaing et al., 2015).

Reducing ultra-processed foods and increasing whole, anti-inflammatory foods supports both gut barrier function and metabolic health.

Prebiotic Support

Prebiotics are fibres that specifically feed beneficial gut bacteria. Foods rich in prebiotics include:

  • Chicory root
  • Garlic and onions
  • Leeks and asparagus
  • Oats and barley
  • Bananas (slightly underripe)
  • Apples

These foods support the growth of bacteria that produce SCFAs and improve insulin sensitivity.

Wellsprout's Role in Supporting Metabolic and Gut Health

Wellsprout Daily Superblend was designed around the principle that metabolic health depends on gut health, and gut health depends on plant diversity.

Our formula includes:

Prebiotic fibres (chicory root, psyllium) that feed beneficial bacteria shown to improve insulin sensitivity

27 whole-food plants providing the dietary diversity associated with healthier gut bacteria and better metabolic outcomes

Anti-inflammatory botanicals (turmeric, ginger) that support both gut health and metabolic function

Important clarification: Wellsprout is not a PMOS treatment. It does not replace medical care or prescribed medications. Wellsprout provides the nutritional support for gut and metabolic wellness, one component of a comprehensive approach to health.

If you have PMOS, work with your healthcare team to develop a treatment plan. Dietary changes, including adding a greens powder, should be discussed with your doctor, particularly if you take medications affecting blood sugar or hormones.

When to See Your Doctor

See your doctor if you experience:

  • Irregular or absent periods
  • Difficulty conceiving
  • Unexplained weight gain, particularly around the abdomen
  • Excessive hair growth (face, chest, back)
  • Acne that doesn't respond to typical treatments
  • Thinning hair on the scalp
  • Dark patches of skin (particularly neck, armpits, groin)
  • Signs of insulin resistance

Ask about testing for:

  • Insulin resistance (fasting insulin, glucose tolerance test)
  • Hormone levels (androgens, LH, FSH)
  • Metabolic markers (lipids, blood pressure, inflammatory markers)
  • Ultrasound (ovarian appearance)

Early diagnosis and intervention can prevent progression to type 2 diabetes and other metabolic complications.

The Bigger Picture: Rethinking Women's Health

The PMOS name change represents something larger than one condition getting renamed.

It's recognition that women's health conditions have historically been reduced to their reproductive components -ovaries, uteruses, hormones - when they're actually whole-body metabolic, inflammatory, and systemic disorders.

PMOS isn't an "ovary problem." It's a metabolic and hormonal condition that affects ovaries along with insulin sensitivity, inflammation, cardiovascular health, mental health, skin health, and long-term disease risk.

And increasingly, research shows that gut health sits at the intersection of all these systems.

Your gut bacteria influence:

  • How you metabolize food and hormones
  • How sensitive your cells are to insulin
  • How much inflammation your body produces
  • How your immune system functions
  • How your brain and hormones communicate

Supporting gut health won't cure PMOS. But understanding the metabolic nature of PMOS and the gut's role in metabolism, opens new pathways for managing the condition and improving quality of life.

Looking Forward

The name change from PCOS to PMOS took 14 years of consensus-building. Implementation will take another three years as medical education, clinical guidelines, and disease classification systems update.

But the science has been pointing this direction for years: PMOS is metabolic, metabolism is connected to gut health, and supporting gut bacteria through diverse plant intake and prebiotic fibre may be one valuable component of comprehensive PMOS management.

As research continues to reveal the mechanisms connecting gut bacteria to insulin sensitivity, hormone metabolism, and inflammation, the role of nutritional support—including targeted prebiotic supplementation and plant diversity—will likely become more prominent in PMOS treatment guidelines.

For now, the name change itself is progress: finally, the medical community is calling this condition what it actually is—a complex metabolic and hormonal disorder requiring whole-body, multisystem care.

Your gut is part of that system. And supporting it might matter more than anyone previously understood.

Related articles:

Looking for gut-friendly recipes to complement your greens powder routine? Browse our Wellsprout recipes designed to support digestive health through whole foods.

Want to assess your current gut health? Take the free gut health quiz and get your personalised score in 2 minutes.

Medical Disclaimer

This article provides educational information only and is not intended as medical advice. PMOS (formerly PCOS) is a medical condition requiring professional diagnosis and management. If you suspect you have PMOS or experience symptoms, consult your doctor for proper testing and treatment.

Wellsprout Daily Superblend is a food supplement, not a PMOS treatment or medication. It does not replace medical care, hormone therapy, or prescribed medications. Any dietary changes, including adding supplements, should be discussed with your healthcare provider, particularly if you have PMOS or take medications affecting hormones or blood sugar.

The research discussed examines connections between gut health and metabolic function. This does not constitute a claim that Wellsprout treats or manages PMOS.

References

Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. (2015). Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature, 519(7541), 92–96. https://doi.org/10.1038/nature14232

Mei, Y., Li, W., Wang, B., Chen, Z., Wu, X., Lin, Y., & Wang, M. (2025). Gut microbiota: an emerging target connecting polycystic ovarian syndrome and insulin resistance. Frontiers in Cellular and Infection Microbiology, 15, 1508893. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933006/

McDonald, D., Hyde, E., Debelius, J. W., Morton, J. T., Gonzalez, A., Ackermann, G., ... Knight, R. (2018). American Gut: An open platform for citizen science microbiome research. mSystems, 3(3), e00031-18. https://doi.org/10.1128/mSystems.00031-18

Qi, X., Yun, C., Sun, L., Xia, J., Wu, Q., Wang, Y., Wang, L., Zhang, Y., Liang, X., Wang, L., Gonzalez, F. J., Patterson, A. D., Liu, H., Mu, L., Zhou, Z., Zhao, Y., Li, R., Liu, P., Zheng, H., ... Jia, W. (2019). Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome. Nature Medicine, 25(8), 1225–1233. https://doi.org/10.1038/s41591-019-0509-0

Teede, H. J., Tay, C. T., Laven, J., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://doi.org/10.1016/S0140-6736(26)00717-8

Torres, P. J., Siakowska, M., Banaszewska, B., Pawelczyk, L., Duleba, A. J., Kelley, S. T., & Thackray, V. G. (2018). Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. Journal of Clinical Endocrinology & Metabolism, 103(4), 1502–1511. https://pubmed.ncbi.nlm.nih.gov/29370410/

Zeng, B., Lai, Z., Sun, L., Zhang, Z., Yang, J., Li, Z., Lin, J., & Zhang, Z. (2019). Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study. Research in Microbiology, 170(1), 43–52. https://pubmed.ncbi.nlm.nih.gov/30292647/

Zhang, J., Sun, Z., Jiang, S., Bai, X., Ma, C., Peng, Q., Chen, K., Chang, H., Fang, T., & Zhang, H. (2019). Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis. mSystems, 4(2), e00017-19. https://doi.org/10.1128/mSystems.00017-19

Zhao, Y., Zhang, C., Huang, Y., Yu, Y., Li, R., Li, M., Liu, N., Liu, P., & Qiao, J. (2021). The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population. Journal of Ovarian Research, 14(1), 50. https://pubmed.ncbi.nlm.nih.gov/33773586/

Zhou, L., Ni, Z., Yu, J., Cheng, W., Cai, Z., Yu, C., & Zhou, L. (2022). Gut microbiome in PCOS associates to serum metabolomics: a cross-sectional study. Scientific Reports, 12(1), 22184. https://pubmed.ncbi.nlm.nih.gov/36564416/

Back to blog